Renal Replacement Anticoagulant Management

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

85000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational comparative effectiveness study of individual patient data using interrupted time series analysis techniques of linked data sources to establish clinical and health economic effects of moving from systemic heparin anticoagulation to regional citrate anticoagulation during continuous renal replacement therapy (CRRT) for patients treated on non-specialist Intensive Care Units (ICUs) in England and Wales.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcomes of Critically Ill Patients Undergoing RRT- a Registry Based Study.

NCT06897254

Renal Replacement Therapies Outcome Assessment

COMPLETED

Investigating Different Anticoagulants for Renal Replacement Therapy

NCT02669589

Acute Kidney Injury

COMPLETED PHASE4

Timing of Renal Replacement Therapy in the Critically Ill Patients

NCT03629977

Acute Kidney Injury Uremia Fluid Overload +2 more

RECRUITING

CRRT Timing in Sepsis-associated AKI in ICU

NCT03175328

Sepsis-Associated Organ Dysfunction RTT

UNKNOWN NA

Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy

NCT01269112

Acute Kidney Injury

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RRAM is an observational comparative effectiveness and cost-effectiveness study of individual patient data using interrupted time series analysis techniques and linked data sources. This study will use existing high quality clinical data collected for the Case Mix programme (CMP) - the national clinical audit for adult critical care - linked with Hospital Episodes Statistics, Office for National Statistics, and UK Renal Registry national data sets to establish the clinical and health economic effects of moving from systemic heparin anticoagulation (SHA) to regional citrate anticoagulation (RCA) during CRRT for patients treated on non-specialist ICUs in England and Wales. This will include data from approximately 85,000 patients treated with CRRT between 1 April 2009 and 31 March 2017 in 184 English non-specialist intensive care units within the ICNARC CMP.

Specific objectives of the RRAM are to:

1. Investigate the short-term benefits, risks, and costs of citrate anticoagulation.
2. Provide information on the subsequent development of end-stage renal disease (ESRD).
3. Trial the efficient research techniques, that if successful could be used to track the effects of any change in critical care practice occurring in ICUs in England and Wales over a reasonably short time scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Critical Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Regional citrate anticoagulation (RCA)

Those receiving regional citrate anticoagulation for CRRT

No interventions assigned to this group

Systemic heparin anticoagulation (SHA)

Those receiving systemic heparin anticoagulation for CRRT

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 16 years or greater
* Admitted to an ICU participating in the ICNARC Case Mix Programme (CMP) in England between 1 April 2009 and 31st March 2017

Exclusion Criteria

* Pre-existing end-stage renal disease (ESRD)
* Admitted to an ICU after kidney or kidney-pancreas transplantation
* Primary admission with acute hepatic failure

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No